

## FIGO GUIDELINES

# Staging classification for cancer of the ovary, fallopian tube, and peritoneum

Jaime Prat ; for the FIGO Committee on Gynecologic Oncology <sup>1</sup>

---

### article info

---

#### Keywords:

Fallopian tube cancer

Ovarian cancer

Peritoneal cancer

Staging

---

### Introduction

Ovarian cancer is the seventh most common cancer diagnosis among women worldwide, and the fifth most common cancer diagnosis among women in higher-resource regions [1]. The world rate is estimated to be 6.3 per 100 000 women, and is highest in high-resource countries (9.3 per 100 000 women) [1]. Primary peritoneal cancer and primary fallopian tube cancer are rare malignancies but share many similarities with ovarian cancer. Clinically, these 3 cancers are managed in a similar manner [2].

The main purpose of staging systems is 2-fold: to provide standard terminology that allows comparison of patients between centers; and to assign patients and their tumors to prognostic groups requiring



Does rupture during surgery worsen prognosis in the absence of excrescences, ascites, or positive washings?

This is controversial. Whereas some studies found that intraoperative capsule rupture portends a higher risk of disease recurrence [19,20], others did not [14,15,18,21,22]. In a multivariable analysis, capsule rupture and positive cytologic washings remained independent predictors of worse disease-free survival [20]. Rupture should be avoided during primary surgery of malignant ovarian tumors confined to the ovaries. Data from several studies suggest that stage I CCC is more frequently stage IC compared with other cell types [17], possibly because of an increased risk of rupture [23].

Are positive washings worse than/the same as capsule rupture?

In multivariable analysis, capsule rupture and positive cytologic washings remained independent predictors of worse disease-free survival [20].

#### Recommendations

€ Histologic type, which in most cases includes grade, should be recorded.

€ All individual subsets of stage IC disease should be recorded.

€ Dense adhesions with histologically proven tumor cells justify upgrading to stage II.

€ If rupture is noted, peritoneal washing and cytology study are indicated.

Stage II: Tumor involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer

T2-N0-M0

IIA: Extension and/or implants on uterus and/or fallopian tubes and/or ovaries

T2a-N0-M0

IIB: Extension to other pelvic intraperitoneal tissues

T2b-N0-M0

#### Comment

Stage II ovarian cancer is still difficult to define. It comprises a small and heterogeneous group making up less than 10% of ovarian cancers. It is defined as extension or metastasis to extraovarian/extratubal pelvic organs and may include curable tumors that have directly extended to adjacent organs but have not yet metastasized, as well as tumors that have seeded the pelvic peritoneum by metastasis and, therefore, have a poor prognosis. Of note, the sigmoid colon is within the pelvis, and therefore sigmoid involvement only is considered stage II. The Committee felt that subdividing this small category further into IIB1 and IIB2 (i.e. microscopic and macroscopic pelvic peritoneal metastases)

was not based on evidence/biology. All stage II disease is treated

into IIIA1(i) (metastasis  $\leq 10$  mm in greatest dimension) and IIIA1(ii) (metastasis  $> 10$  mm in greatest dimension), even if there are no

- [12] Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynecol Obstet* 2006;95(Suppl. 1):S161-92.
- [13] Yemelyanova AV, Cosin JA, Bidus MA, Boice CR, Seidman JD. Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. *Int J Gynecol Cancer* 2008;18(3):465-9.
- [14] Seidman JD, Yemelyanova AV, Khedmati F, Bidus MA, Dainty L, Boice CR, et al. Prognostic factors for stage I ovarian carcinoma. *Int J Gynecol Pathol* 2010;29(1):1-7.
- [15] Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjørstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. *Obstet Gynecol* 1990;75(2):263-73.
- [16] Ozols RF, Rubin SC, Thomas GM. Epithelial Ovarian Cancer. In: Hoskins WJ, Young RC, Markman M, Perez CA, Barakat R, Randall M, editors. *Principles and Practice of Gynecologic Oncology*. 4th ed. New York: Lippincott; 2005. p. 895-987.
- [17] Seidman JD, Cosin JA, Wang BG, Alsop S, Yemelyanova A, Fields A, et al. Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: a clinicopathologic study of 84 patients originally classified as FIGO stage II. *Gynecol Oncol* 2010;119(2):250-4.
- [18] Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. *J Clin Oncol* 1996;14(11):2968-75.
- [19] Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelde P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. *Lancet* 2001;357(9251):176-82.
- [20] Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, et al. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. *Obstet Gynecol* 2009;113(1):11-7.
- [21] Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. *Cancer* 2008;112(10):2202-10.
- [22] Obermair A, Fuller A, Lopez-Varela E, van Gorp T, Vergote I, Eaton L, et al. A new prognostic model for FIGO stage I epithelial ovarian cancer. *Gynecol Oncol* 2007;104(3):607-11.
- [23] Timmers PJ, Zwinderman AH, Teodorovic I, Vergote I, Trimbois JB. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. *Int J Gynecol Cancer* 2009;19(1):88-93.
- [24] Harter P, Gnauer K, Hils R, Lehmann TG, Fisseler-Eckhoff A, Traut A, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. *Int J Gynecol Cancer* 2007;17(6):1238-44.
- [25] Ayhan A, Gultekin M, Dursun P, Dogan NU, Aksan G, Guven S, et al. Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? *Gynecol Oncol* 2008;108(2):428-32.
- [26] Euscher ED, Silva EG, Deavers MT, Elishaev E, Gershenson DM, Malpica A. Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. *Am J Surg Pathol* 2004;28(9):1217-23.
- [27] Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. *Cancer* 1998;83(8):1555-60.
- [28] Kanazawa K, Suzuki T, Tokashiki M. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. *Gynecol Oncol* 1999;73(2):237-41.
- [29] Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. *J Natl Cancer Inst* 2005;97(8):560-6.
- [30] Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? *Gynecol Oncol* 2006;103(3):797-801.
- [31] Ferrandina G, Scambia G, Legge F, Petrillo M, Salutari V. Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B. *Gynecol Oncol* 2007;107(1):154-6.
- [32] Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, et al. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. *J Gynecol Oncol* 2008;19(4):223-8.
- [33] Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern. *Am J Surg Pathol* 2007;31(11):1611-20.